December 1, 2016 - By Louis Casey · 0 Comments
The stock of Cytori Therapeutics DE (NASDAQ:CYTX) registered a decrease of 8.75% in short interest. CYTX’s total short interest was 436,900 shares in December as published by FINRA. Its down 8.75% from 478,800 shares, reported previously. With 42,100 shares average volume, it will take short sellers 10 days to cover their CYTX’s short positions. The short interest to Cytori Therapeutics DE’s float is 2.44%. The stock decreased 2.82% or $0.04 on November 30, hitting $1.55. Cytori Therapeutics Inc (NASDAQ:CYTX) has declined 69.61% since April 28, 2016 and is downtrending. It has underperformed by 75.53% the S&P500.
Cytori Therapeutics, Inc. is a biotechnology firm engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The company has a market cap of $31.90 million. The Firm develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It currently has negative earnings. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation.
Out of 3 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Cytori Therapeutics has been the topic of 4 analyst reports since August 8, 2015 according to StockzIntelligence Inc. On Monday, August 10 the stock rating was maintained by TH Capital with “Buy”. The stock of Cytori Therapeutics Inc (NASDAQ:CYTX) has “Hold” rating given on Friday, September 4 by Zacks. The rating was maintained by Maxim Group with “Buy” on Saturday, August 8.
More news for Cytori Therapeutics Inc (NASDAQ:CYTX) were recently published by: Thestreet.com, which released: “Cytori Therapeutics (CYTX) Stock Spikes Today on Chinese Approval of …” on April 06, 2015. Businesswire.com‘s article titled: “Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan” and published on June 27, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey